GSK Get The Go-ahead for Acquisition of Novartis’ Vaccines Business

Regulatory update on transaction with Novartis November 26, 2014 GlaxoSmithKline plc is today providing this update to its announcement of 22 April 2014 relating to the major three-part transaction with Novartis AG (the Original Announcement). The US Federal Trade Commission (FTC) has voted to approve GSK’s proposed acquisition of Novartis’s vaccines business (excluding influenza vaccines) and the proposed creation of …

GSK Statement on First Phase 1 Trial Results of a Candidate Ebola Vaccine

November 24, 2014 First results from a small phase 1 trial published today in the New England Journal of Medicine show that a GSK/NIH Ebola candidate vaccine was well-tolerated and produced an immunological response in each of the 20 healthy adult volunteers in the USA who received it. The candidate vaccine used in the trial conducted by the National Institutes …

Merck enters the Ebola Vaccine Race in NewLink Partnership

Merck obtains the rights to NewLink genetics’ experimental Ebola Vaccine, putting pressure on GSK Merck has struck a agreement with NewLink Genetics to licence their investigational Ebola vaccine, rVSV-EBOV. The $50 million agreement gives Merck exclusive rights to develop, manufacture, and distribute the vaccine across the world. This partnership should allow NewLink to keep pace with the huge effort by …

Sanofi’s Dengue Vaccine To Market in 2015

Sanofi Pasteur announces a successfull phase III trial in Latin America and plans to enter the market in 2015 The vaccines division of Sanofi  has published the results of their second phase III trial of their dengue vaccine candidate. The study, published in The New England Journal of Medicine, looked at the efficacy of the vaccine in Latin America, and …

Nine-valent HPV Vaccine May Prevent Nearly 90 Percent of Cervical Cancers

October 1, 2014 Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. “We wanted to study how …

Amongst the flurry of efforts to combat the West African Ebola outbreak, Johnson & Johnson is trying its hand at developing a vaccine

Johnson & Johnson To Fast Track Ebola Vaccine Trials

Amongst the flurry of efforts to combat the West African Ebola outbreak, Johnson & Johnson is trying its hand at developing a vaccine Johnson & Johnson can be counted amongst the ranks of yet another pharmaceutical company that has joined the race to develop an Ebola vaccine. Thus far, the most advanced vaccine candidate is Glaxo Smith Kline’s, which is the …

Ebola vaccine trials fast-tracked by international consortium

Unprecedented international consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine August 28, 2014 A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people …

Researchers at Stanford Retract Narcolepsy Study Linked to GSK’s Swine Flu Vaccine

Stanford University researchers have retracted a major study that sought to explain why some abruptly fell asleep after receiving Pandemrix vaccine Researchers at the University of Stanford School of Medicine have retracted a study they published last year which endeavoured to explain why some people were falling asleep after receiving a GSK Swine Flu vaccine called Pandemrix. The researchers behind …

Pfizer bid for GSK ‘has some merits’, says Berenberg

August 1st, 2014 Could Pfizer acquire GlaxoSmithKline as a “plan B” after failing to land AstraZeneca? It would be a stretch but not totally impossible, according to analysts at Berenberg Bank. GSK’s market capitalisation has slumped to $117 billion (£69.49 billion), or just under Pfizer’s failed offer for AstraZeneca, following weak quarterly results and a warning on full-year profits last …